ArticleFrontiers in radiology2026
Multi-scale Gaussian product-of-experts for missing sequence multiple sclerosis lesion segmentation.
Article in Frontiers in radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and evaluate a unified framework for multiple sclerosis (MS) white matter lesion segmentation that operates robustly under clinically prevalent missing sequence magnetic resonance imaging conditions. Methods: We propose a multi-scale Gaussian product-of-experts framework (MG-PoE) integrated into nnU-Net, where sequence-specific inputs are independently processed through a shared encoder and parameterized as Gaussian experts before combination through precision-weighted product-of-experts (PoE) fusion at each encoder scale. The unified fusion rule handles different sequence configurations without requiring subset-specific architectures. The framework was systematically evaluated under different sequence configurations on diverse datasets (MSSEG2016, MS3SEG, and MSLesSeg24). Results: On the five-sequence MSSEG2016, the proposed framework achieved the best overall performance compared to benchmark methods across all full-sequence and partially observed multisequence settings, with a mean Dice Similarity Coefficient (DSC) of 0.7029, a mean 95th percentile Hausdorff distance (HD95) of 22.4030, and a mean Composite Score (CS) of 0.7235 across the 26 sequence configurations. On MS3SEG, MG-PoE achieved the highest mean DSC and CS across the full sequence and missing-sequence settings, with significant improvements over competing methods, while HD95 performance was generally comparable. In zero-shot evaluation on MSLesSeg24, the method achieved the best overall DSC and HD95 in the full sequence setting (DSC, 0.5566; HD95, 27.3729) and the best mean DSC, HD95 and CS across the missing-sequence settings (DSC, 0.5096; HD95, 30.5054; CS, 0.5811). Conclusion: The MG-PoE framework provides a unified approach to missing-sequence MS lesion segmentation, achieving favorable performance on independent datasets and providing initial evidence of cross-dataset robustness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.